Screener
Denali Therapeutics Inc. DNLI Business Segments — Personnel related selling, general and administrative expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept dnli:PersonnelRelatedSellingGeneralAndAdministrativeExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other research and development expenses, including small molecule programs | 16,494 | 24,847 | 40,048 | 54,347 |
| Personnel related research and development expenses | 40,106 | 40,255 | 81,934 | 80,524 |
| Total research and development expenses | 97,019 | 102,696 | 200,865 | 218,923 |
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | $750 | — | $750 | — |
| Segment operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — personnel related selling, general and administrative expenses?
- Denali Therapeutics Inc. (DNLI) reported business segments — personnel related selling, general and administrative expenses of $22.92M in Q2 2026.
- What does business segments — personnel related selling, general and administrative expenses mean?
- This metric represents the total compensation and benefits costs for administrative, executive, and support staff specifically allocated to the therapeutics development segment. It reflects the fixed operational investment required to maintain the human capital necessary for advancing drug discovery and clinical programs. Monitoring this figure helps investors assess the efficiency of the company's organizational structure in supporting its core biotechnology research activities.
Ask your AI about Denali Therapeutics Inc.'s business segments — personnel related selling, general and administrative expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude